This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies.  Read our Cookies Policy.
Close
Eye News
  • Features
    • Close
    • Features
    • Allied Professions
    • Humanitarian
    • Interviews
    • AI & Oculomics
    • Ophthalmology
    • Optometry
    • Podcast videos
    • Supplements
  • Education
    • Close
    • Education
    • Learning Curve
    • Quiz
    • Top Tips
    • Trainees
    • Medico-Legal
    • The Truth Behind The Headlines
    • Case Reports
    • Pete's Bogus Journey
  • Reviews
    • Close
    • Reviews
    • Book Reviews
    • Journal Reviews
    • What's trending?
    • Tech Reviews
    • My Top Five
    • The Culture Section
  • Events
  • News
  • Product Guide
  • Industry News
  • Contact us
    • Close
    • Contact us
    • Write for Eye News
  • Home
  • Reviews
  • Journal Reviews
  • Anatomical and functional outcomes following switching from aflibercept to ranibizumab in NARMD

Anatomical and functional outcomes following switching from aflibercept to ranibizumab in NARMD
Reviewed by Jonathan Chan

5 June 2020 | Jonathan Chan | EYE - Vitreo-Retinal
Share This

This is a six-month, prospective, single-arm study in the UK and Germany. A total of 100 patients were enrolled (one in the primary failure group, 99 in the suboptimal treatment response group), treated three-monthly intravitreal ranibizumab injections (0.5mg), and then pro re nata at monthly visits. The primary endpoint was change from baseline (CFB) to day 90 in central subfield retinal thickness (CSRT). A significant CFB was found in median CSRT of -30.75um (p,0.0001) to day 90. Maximum pigment epithelial detachment (PED) and intraretinal cyst (IRC) height, intraretinal fluid and subretinal fluid in qualitative optical coherence tomography (OCT) parameters were also reduced. In the EDTRS letters assessed by the groups, 55% and 59% of patients gained 0->15 letters versus baseline, at day 90 and day 180, respectively. Mean improvements in best corrected visual acuity (BCVA) (CFB) to each time point were small (up to two letters). The authors concluded that the SAFARI study showed switching to ranibizumab following an inadequate response or loss of efficacy whilst aflibercept led to a significant improvement in the primary efficacy end point of CSRT with approximately 60% achieving stabilised or improved VA. Patients with neovascular age-related macular degeneration (nARMD) who have shown suboptimal response to aflibercept may benefit from switching to ranibizumab.

Anatomical and functional outcomes following switching from aflibercept to ranibizumab in neovascular age-related macular degeneration (NARMD) in Europe: safari study.
Gale RP, Pearce I, Eter N, et al.
BRITISH JOURNAL OF OPHTHALMOLOGY
2020;104:493-9.
Share This
CONTRIBUTOR
Jonathan Chan

Royal Hallamshire Hospital, Sheffield, UK.

View Full Profile
Specialty
  • EYE - Cataract
  • EYE - Cornea
  • EYE - General
  • EYE - Glaucoma
  • EYE - Neuro-ophthalmology
  • EYE - Oculoplastic
  • EYE - Oncology
  • EYE - Orbit
  • EYE - Paediatrics
  • EYE - Pathology
  • EYE - Refractive
  • EYE - Strabismus
  • EYE - Vitreo-Retinal
Archive
  • 2025
  • 2024
  • 2023
  • 2022
  • 2021
  • 2020
  • 2019
  • 2018
  • 2017
  • 2016
  • 2015
  • 2014
  • 2013

Top Of Page

9 Gayfield Square, 
Edinburgh EH1 3NT, UK.

Call: +44 (0)131 557 4184
www.pinpoint-scotland.com

WEBSITE DETAILS
  • Cookie Policy
  • Data Protection Notice
  • Privacy Policy
  • Terms and Conditions
ABOUT US
  • Who we are
  • Register
  • Contact us
  • Contributors
  • Company Awards
DIGITAL ISSUES/GUIDELINES
  • Digital issues - Library
  • Supplements - Library
  • Guidelines
Accreditations
IPSO_FLAG_TEAL 2025.png cpdcertified.png

Pinpoint Scotland Ltd (Registered in Scotland No. SC068684) | © 2025 - Website by Gecko Agency